Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs

Contact: Kurt Leutzinger Abgenix, Inc. Vice President and Chief Financial Officer (510) 608-6575 Marion E. Glick Porter Novelli (212) 601-8273 Mark R. Vincent CuraGen Corporation Director, Corporate Communications 1-888-GENOMICS www.curagen.com ABGENIX AND CURAGEN ESTABLISH LARGE-SCALE DRUG DEVELOPMENT ALLIANCE Companies to Develop Genomics-based Human Antibody Drugs Fremont, CA and New Haven, CT - December 9, 1999 - Abgenix, Inc. (Nasdaq: ABGX), an antibody-based biopharmaceutical company and CuraGen Corporation (Nasdaq: CRGN), an integrated genomics-based drug discovery and development company, announced today the formation of a strategic alliance to develop and commercialize genomics-based antibody drugs using XenoMouse technology. This five-year alliance has been established to identify up to 120 fully human antibody drugs intended for treating a broad range of complex diseases including cancer and autoimmune disorders. Antibodies to cancer antigens in CuraGen's database will be generated exclusively with Abgenix' XenoMouse technology during this alliance. Under the terms of this agreement, Abgenix will purchase $15 million of CuraGen common stock and CuraGen will provide research support payments of $1.5 million per year. In addition, both companies will receive reciprocating milestone and royalty payments for products resulting from this drug development alliance. "Abgenix is impressed with CuraGen's technical capabilities with integrated genomics-based drug discovery and development," stated R. Scott Greer, president and CEO of Abgenix. "This strategic alliance complements our existing relationship with Human Genome Sciences and significantly expands our presence in the genomics field. We are also pleased to be joining Biogen and Genentech as corporate partners with equity stakes in CuraGen." "This strategic alliance changes the drug development landscape by establishing a powerful platform for producing genomics-base

Contact: Kurt Leutzinger, Abgenix, Inc.
Porter Novelli

Page: 1 2 3 4

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix initiates phase III clinical trial of graft versus host disease therapy
3. Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. Tufts University establishes $4 million dollar tissue engineering resource center
8. Corals can reestablish symbiosis with algae from their environments after bleaching
9. Researchers establish first molecular link between eating and aging
10. DFG establishes first German-Sino Research Training Group
11. New Woods Hole Center for Oceans and Human Health established

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: